Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Indivior Pharmaceuticals (INDV) Equity Average (2024 - 2026)

Indivior Pharmaceuticals has reported Equity Average over the past 3 years, most recently at -$121.0 million for Q1 2026.

  • For Q1 2026, Equity Average rose 61.09% year-over-year to -$121.0 million; the TTM value through Mar 2026 reached -$121.0 million, up 61.09%, while the annual FY2025 figure was -$217.5 million, 16.51% up from the prior year.
  • Equity Average for Q1 2026 was -$121.0 million at Indivior Pharmaceuticals, up from -$152.5 million in the prior quarter.
  • Over five years, Equity Average peaked at -$121.0 million in Q1 2026 and troughed at -$323.5 million in Q4 2024.
  • A 3-year average of -$233.3 million and a median of -$232.0 million in 2025 define the central range for Equity Average.
  • Biggest five-year swings in Equity Average: tumbled 80.29% in 2025 and later skyrocketed 61.09% in 2026.
  • Year by year, Equity Average stood at -$323.5 million in 2024, then skyrocketed by 52.86% to -$152.5 million in 2025, then grew by 20.66% to -$121.0 million in 2026.
  • Business Quant data shows Equity Average for INDV at -$121.0 million in Q1 2026, -$152.5 million in Q4 2025, and -$232.0 million in Q3 2025.